Loading the company…
Loading the company…
In the last ten years FDA made 0 decisions for Erbe (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family. The latest was on 2015-05-04.
| Family | Decisions on record |
|---|---|
| Tumor ablation | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2015-05-04 | 510(k) | K151041 | ERBECRYO 2 Cryosurgical Unit with accessories |
| 2005-07-27 | 510(k) | K051509 | ERBE ERBOKRYO CA CRYOSURGICAL UNIT & ACCESSORIES |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Erbe.
In 2025, Erbe reported engagement with 450 surgeons and other clinicians in the states MedaRep covers, worth $56K in consulting, speaking, meals and travel for its device products, the most in Florida ($7,722 to 23). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($7,722, 23 engaged), California ($6,870, 79 engaged), New York ($5,152, 29 engaged), Illinois ($4,593, 31 engaged), Arizona ($4,226, 7 engaged).